Many nutrients are critical for maintaining brain structure and function, including cognition. A deficiency of some nutrients can lead to compromised brain structure and function, which accelerates brain aging. Additional nutrients may have benefits when provided in quantities greater than those listed in recognized requirements, whereas other nutrients that may be beneficial to cognitive function may not be recognized as essential nutrients. The purpose of the information provided here was to summarize the evidence for beneficial effects of nutrients on brain function and cognition, with an emphasis on the aging brain, and to provide evidence on the dietary management of dogs with cognitive dysfunction syndrome.
The authors declare there were no conflicts of interest.
Medium-chain fatty acid
Polyunsaturated fatty acid
Patterson EE, Munana KR, Kirk CA, et al. Results of a ketogenic food trial for dogs with idiopathic epilepsy (abstr). J Vet Intern Med 2005; 19:421.
Underwood M, Sivesind P, Gabourie T. Effect of apoaequorin on cognitive function (abstr). J Alzheimers Dementia 2011;7:e65.
Zanghi B, Araujo J, Milgram NW. PM-supplementation with melatonin, zinc, and Haematococcus pluvialis selectively improves attention and motor learning in aged, memory-impaired dogs (abstr). J Vet Intern Med 2014;28:1087.
Aktivait, VetPlus, Lytham St Annes, England.
Senilife, Ceva Animal Health, Lenexa, Kan.
Cholodin, MVP Laboratories Inc, Omaha, Neb.
Zylkene, Vetoquinol, Fort Worth, Tex.
1. Cummings BJ, Head E, Ruehl W, et al. The canine as an animal model of human aging and dementia. Neurobiol Aging 1996;17:259–268.
2. Milgram NW. Cognitive experience and its effect on age-dependent cognitive decline in Beagle dogs. Neurochem Res 2003;28:1677–1682.
4. Schütt T, Helboe L, Pedersen L, et al. Dogs with cognitive dysfunction syndrome as a spontaneous model for early Alzheimer's disease: a translational study of neuropathological and inflammatory markers. J Alzheimers Dis 2016;52:433–449.
5. Youssef SA, Capucchio MT, Rofina JE, et al. Pathology of the aging brain in domestic and laboratory animals, and animal models of human neurodegenerative diseases. Vet Pathol 2016;53:327–348.
6. Chapagain D, Virányi Z, Huber L, et al. Effect of age and dietary intervention on discrimination learning in pet dogs. Front Psychol 2018;9:2217.
7. Giaccone G, Verga L, Finazzi M, et al. Cerebral preamyloid deposits and congophilic angiopathy in aged dogs. Neurosci Lett 1990;114:178–183.
8. Cummings BJ, Su JH, Cotman CW, et al. β-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging 1993;14:547–560.
9. Cummings BJ, Su JH, Cotman CW, et al. β-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 1996;66:11–23.
10. Head E, Callahan H, Muggenburg BA, et al. Visual-discrimination learning ability and β-amyloid accumulation in the dog. Neurobiol Aging 1998;19:415–425.
11. Su MY, Head E, Brooks WM, et al. Magnetic resonance imaging of anatomic and vascular characteristics in a canine model of human aging. Neurobiol Aging 1998;19:479–485.
14. Head E, Moffat K, Das P, et al. β-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging 2005;26:749–763.
15. Pugliese M, Gangitano C, Ceccariglia S, et al. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes. Brain Res 2007;1139:85–94.
16. Head E, Rofina J, Zicker S. Oxidative stress, aging, and central nervous system disease in the canine model of human brain aging. Vet Clin North Am Small Anim Pract 2008;38:167–178.
18. Yu CH, Song GS, Yhee JY, et al. Histopathological and immunohistochemical comparison of the brain of human patients with Alzheimer's disease and the brain of aged dogs with cognitive dysfunction. J Comp Pathol 2011;145:45–58.
23. Romanucci M, Della Salda L. Oxidative stress and protein quality control systems in the aged canine brain as a model for human neurodegenerative disorders. Oxid Med Cell Longev 2015:2015:940131.
24. Smolek T, Madari A, Farbakova J, et al. Tau hyperphosphorylation in synaptosomes and neuroinflammation are associated with canine cognitive impairment. J Comp Neurol 2016;524:874–895.
27. Mergenthaler P, Lindauer U, Dienel G, et al. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 2013;36:587–597.
28. Grimm A, Friedland K, Eckert A. Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease. Biogerontology 2016;17:281–296.
30. Yin F, Sancheti H, Patil I, et al. Energy metabolism and inflammation in the brain aging and Alzheimer's disease. Free Radic Biol Med 2016;100:108–122.
31. London ED, Ohata M, Takei H, et al. Regional cerebral metabolic rate for glucose in Beagle dogs of different ages. Neurobiol Aging 1983;4:121–126.
32. Head E, Liu J, Hagen TM, et al. Oxidative damage increases with age in a canine model of human brain aging. J Neurochem 2002;82:375–381.
33. Nugent S, Tremblay S, Chen K, et al. Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiol Aging 2014;35:1386–1395.
34. Butterfield DA, Reed T, Newman SF, et al. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007;43:658–677.
35. Davis PR, Head E. Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. Front Pharmacol 2014;5:47.
36. Landsberg GM, Denenberg S, Araujo J. Cognitive dysfunction in cats: a syndrome we used to dismiss as ‘old age.'. J Feline Med Surg 2010;12:837–848.
37. Landsberg GM, Nichol J, Araujo JA. Cognitive dysfunction syndrome: a disease of canine and feline brain aging. Vet Clin North Am Small Anim Pract 2012;42:749–768.
38. de Rivera C, Boutet I, Zicker S, et al. A novel method for assessing contrast sensitivity in the Beagle dog is sensitive to age and an antioxidant-enriched food. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:379–387.
39. Salvin H, McGreevy P, Sachdev P, et al. Growing old gracefully—behavioral changes associated with “successful aging” in the dog, Canis familiaris. J Vet Behav Clin Appl Res 2011;6:313–320.
40. Fast R, Schütt T, Toft N, et al. An observational study with long-term follow-up of canine cognitive dysfunction: clinical characteristics, survival and risk factors. J Vet Intern Med 2013;27:822–829.
42. Schütt T, Toft N, Berendt M. Cognitive function, progression of age-related behavioral changes, biomarkers and survival in dogs more than 8 years old. J Vet Intern Med 2015;29:1569–1577.
43. Madari A, Farbakova J, Katina S, et al. Assessment of severity and progression of canine cognitive dysfunction syndrome using the Canine Dementia Scale (CADES). Appl Anim Behav Sci 2015;171:138–145.
44. Gunn-Moore D, Moffat K, Christie L, et al. Cognitive dysfunction and the neurobiology of ageing in cats. J Small Anim Pract 2007;48:546–553.
46. McCune S, Stevenson J, Fretwell L, et al. Ageing does not significantly affect performance in a spatial learning task in the domestic cat (Felis silvestris catus). Appl Anim Behav Sci 2008;112:345–356.
49. Nugent S, Courchesne-Loyer A, St-Pierre V, et al. Ketones and brain development: implications for correcting deteriorating brain glucose metabolism during aging. Oilseeds Fats Crops Lipids 2016;23:D110.
50. Broom GM, Shaw IC, Rucklidge JJ. The ketogenic diet as a potential treatment and prevention strategy for Alzheimer's disease. Nutrition 2019;60:118–121.
51. Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev 1999;15:412–426.
52. Cunnane SC, Courchesne-Loyer A, St-Pierre V, et al. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease. Ann N Y Acad Sci 2016;1367:12–20.
53. Cunnane SC, Courchesne-Loyer A, Vandenberghe C, et al. Can ketones help rescue brain fuel supply in later life? Implications for cognitive health during aging and the treatment of Alzheimer's Disease. Front Mol Neurosci 2016;9:53.
54. Freemantle E, Vandal M, Tremblay-Mercier J, et al. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot Essent Fatty Acids 2006;75:213–220.
55. Hertz L, Chen Y, Waagepetersen H. Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, β-amyloid toxicity, and astrocyte function. J Neurochem 2015;134:7–20.
56. Taylor MK, Sullivan DK, Mahnken JD, et al. Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease. Alzheimers Dement (N Y) 2017;4:28–36.
59. Payne NE, Cross JH, Sander JW, et al. The ketogenic and related diets in adolescents and adults—a review. Epilepsia 2011;52:1941–1948.
61. de Bruijne JJ, Altszuler N, Hampshire J, et al. Fat mobilization and plasma hormone levels in fasted dogs. Metabolism 1981;30:190–194.
62. Puchowicz MA, Smith CL, Bomont C, et al. Dog model of therapeutic ketosis induced by oral administration of R,S-1,3-butanediol diacetoacetate. J Nutr Biochem 2000;11:281–287.
65. USDA. USDA Agricultural Research Service. National nutrient database for standard reference release 28. Available at: ndb.nal.usda.gov/ndb/search/list. Accessed May 26, 2019.
66. Augustin K, Khabbush A, Williams S, et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol 2018;17:84–93.
67. Jensen GL, McGarvey N, Taraszewski R, et al. Lymphatic absorption of enterally fed structured triacylglycerol vs physical mix in a canine model. Am J Clin Nutr 1994;60:518–524.
68. Newton JD, McLoughlin MA. Transport pathways of enterally administered medium-chain triglycerides in dogs, in Proceedings. Iams Nutr Symp, 2000;143–152.
69. Pan Y, Larson B, Araujo JA, et al. Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. Br J Nutr 2010;103:1746–1754.
70. Law TH, Davies ESS, Pan Y, et al. A randomised trial of medium-chain TAG as treatment for dogs with idiopathic epilepsy. Br J Nutr 2015;114:1438–1447.
71. Khabbush A, Orford M, Tsai Y, et al. Neuronal decanoic acid oxidation is markedly lower than that of octanoic acid: a mechanistic insight into the medium-chain triglyceride ketogenic diet. Epilepsia 2017;58:1423–1429.
72. Studzinski CM, MacKay WA, Beckett TL, et al. Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-β precursor protein (APP) levels in the aged dog. Brain Res 2008;1226:209–217.
73. Paleologou E, Ismayilova N, Kinali M. Use of the ketogenic diet to treat intractable epilepsy in mitochondrial disorders. J Clin Med 2017;6:56.
74. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 2009;59:293–315.
75. Wang D, Mitchell E. Cognition and synaptic-plasticity related changes in aged rats supplemented with 8- and 10-carbon medium chain triglycerides. PLoS One 2016;11:e0160159.
76. Taha AY, Henderson ST, Burnham WM. Dietary enrichment with medium chain triglycerides (AC-1203) elevates polyunsaturated fatty acids in the parietal cortex of aged dogs: implications for treating age-related cognitive decline. Neurochem Res 2009;34:1619–1625.
77. Hall JA, Jewell DE. Feeding healthy Beagles medium-chain triglycerides, fish oil, and carnitine offsets age-related changes in serum fatty acids and carnitine metabolites. PLoS One 2012;7:e49510.
78. Kashiwaya Y, Takeshima T, Mori N, et al. D-β-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci U S A 2000;97:5440–5444.
79. Duthie SJ, Whalley LJ, Collins AR, et al. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908–913.
80. Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J Nutr Health Aging 2006;10:377–385.
81. Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 2: macronutrients. J Nutr Health Aging 2006;10:386–399.
83. de Jager CA, Oulhag A, Jacoby R, et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 2012;27:592–600.
84. Oulhaj A, Jernerén F, Refsum H, et al. Omega-3 fatty acid status enhances the prevention of cognitive decline by B vitamins in mild cognitive impairment. J Alzheimers Dis 2016;50:547–557.
85. Vauzour D, Camprubi-Robles M, Miguel-Kergoat S, et al. Nutrition for the ageing brain: towards evidence for an optimal diet. Ageing Res Rev 2017;35:222–240.
87. Solfrizzi V, Agosti P, Lozupone M, et al. Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: a systematic review. Neurosci Biobehav Rev 2018;95:480–498.
88. Pan Y, Kennedy